1 DNA Way
South San Francisco
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1204 articles with Genentech, Inc.
Xofluza (baloxavir marboxil) was approved for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. The new medication has a novel mechanism of action that, Roche said, inhibits polymerase acidic endonuclease, an enzyme that is essential for the flu virus t...
10/25/2018What is presumably good humor, Cambridge, Mass.-based Syros Pharmaceuticals held its third annual Lab Olympics, where various executives in the company competed in a range of contests that included a race to put on safety equipment and accuracy in pipetting.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Food and Drug Administration (FDA) has approved XOFLUZA™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older.
Mesothelioma is a rare cancer that develops in the lining of the lungs, abdomen, or cardiovascular cavity. A 2017 study reported that the number of people affected by this rare cancer is between 2,400 - 2,800 individuals per year in the United States alone.
Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
The Phase III IMpower130 study investigating the Tecentriq plus chemotherapy combination demonstrated a significant overall survival (OS) and progression-free survival (PFS) benefit
Updated with Exclusive | ESMO 2018: 60% of Ovarian Cancer Patients Receiving Lynparza Were Progre...
10/22/2018AstraZeneca and Merck & Co. presented results at the Presidential Symposium at the European Society for Medical Oncology 2018 Congress held in Munich Germany describing its Phase III SOLO-1 trial of Lynparza (olaparib) in ovarian cancer.
The European Society of Medical Oncology was in full swing this weekend as multiple companies showed off mid- and late-stage assets that could change the way some patients are treated for their cancer. This morning, BioSpace takes a look at some of the announcements.
Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors
Entrectinib showed response irrespective of tumor type or spread to the central nervous system (CNS)
Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved an update to the Rituxan®
Every year, the Breakthrough Prize Foundation awards a collective total of $22 million to nine researchers for achievements in the Life Sciences, Fundamental Physics and Mathematics.
10/18/2018The company, with sites in Seattle and South San Francisco, focuses on next-generation oncology therapeutics. It recently completed a portfolio review and decided to focus its energies and existing capital on G100 and abandoned its CMB305 program.
Two well-established pharma companies are expanding in two different U.S. cities. One city is known for the plethora of pharma and biotech jobs, while the other is in an area that might not immediately spring to mind when it comes to biotech hubs.
Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
Phase III KATHERINE study shows Kadcyla® significantly improved invasive disease-free survival compared to Herceptin® in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.
OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression Over Five Years in Relapsing and Primary Progressive Multiple Sclerosis
People with relapsing MS (RMS) treated sooner with OCREVUS had earlier reduction in disease activity and less disability progression vs. those who switched from interferon beta-1α
Genentech, a Roche company, released data from a long-term clinical trial of Ocrevus in multiple sclerosis. Meanwhile, Novartis isn’t standing still on MS. Earlier this week the company announced that both the FDA and EMA had accepted its NDA and MAA, respectively, for siponimod.
Celgene Corporation presented data at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Berlin, Germany with results from two Phase III trials.